Inactief instrument

Andere talen AgeX Therapeutics, Inc.

Aandelen

AGE

US00848H2076

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Serina Therapeutics, Inc. completed the acquisition of AgeX Therapeutics, Inc. from a group of shareholders in a reverse merger transaction.	26/03
AgeX Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	22/03
AgeX Therapeutics Reports Fourth Quarter and Annual 2023 Financial Results	22/03
AGEX THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of AgeX Therapeutics, Inc. - AGE	27/02
AgeX Therapeutics, Inc. Appoints Steven Mintz as a Director, Member of Audit Committee, Compensation Committee and Nominating & Corporate Governance Committee	11/01
AgeX Therapeutics : New Financial Obligation - Form 8-K	28/12
AgeX Therapeutics : Termination of Material Agreement - Form 8-K	01/12
Agex Therapeutics, Inc. Terminates Nafees Malik as Chief Operating Officer, Effective on December 27, 2023	01/12
Pfizer Signs License Agreement With Serina Therapeutics to Gain Access to POZ Polymer Technology	17/11
Earnings Flash (AGE) AGEX THERAPEUTICS Posts Q3 Revenue $67,000	14/11
AgeX Therapeutics Reports Third Quarter 2023 Financial Results	14/11
AgeX Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11
AgeX Therapeutics : New Financial Obligation - Form 8-K	06-10-23
AgeX Therapeutics, Inc. Announces Departure of Dr. Michael H. May as Director of the Company	08-09-23
AGEX THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of AgeX Therapeutics, Inc. - AGE	06-09-23
AGE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of AgeX Therapeutics, Inc. Is Fair to Shareholders	30-08-23
Serina Therapeutics and AgeX Therapeutics Enter into Merger Agreement	30-08-23
Serina Therapeutics, Inc. entered into a merger agreement to acquire AgeX Therapeutics, Inc. from shareholders in a reverse merger transaction.	30-08-23
AgeX Therapeutics : New Financial Obligation - Form 8-K	25-08-23
Earnings Flash (AGE) AGEX THERAPEUTICS Posts Q2 Revenue $9,000	14-08-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen AgeX Therapeutics, Inc.

Aandelen

AGE

US00848H2076

Andere talen

Filters